23andMe
Earlier this week the Food and Drug Administration sent a warning letter to the direct to consumer gene testing company 23andMe ordering the company to stop marketing its $99 genotype screening test. So what are the FDA's bureaucrats worried about? Evidently they fear that purchasers of 23andMe's personal genome services will do something dangerously stupid in reaction to the genetic risk information that the tests provide. Reason Science Correspondent Ronald Bailey points out that the FDA has offered no evidence that 23andMe test results are going to produce an outbreak of do-it-yourself mastectomies.
Comments